Can a California 'March-In' Save Terminally Ill 'Bubble Babies?'

Can the leaders of the $12 billion California stem cell agency “march in” and force the use of a genetic treatment to save the lives of children with a rare, fatal affliction known as the bubble baby disease? 

They can try. 

But the battle could be long and the outcome in considerable doubt. At stake, nonetheless, are the babies born with a genetic defect…